News

Eli Lilly's Investigational Oral Pill Shows Weight Loss Benefits With Lingering Side Effect Concerns
Eli Lilly's orforglipron reduced A1C and weight in type 2 diabetes, while weekly insulin efsitora matched daily insulin with ...
India Today on MSN3d
Eli Lilly's oral pill shows similar results to popular weight-loss drugs
A new oral anti-diabetes pill, orforglipron, shows similar effectiveness to injectable GLP-1 drugs in a Phase 3 trial.
New diabetes drug may outperform Ozempic jab
The first diabetes and obesity pill that is similar to Ozempic — but in tablet form — may actually outperform the popular ...
GLP-1 Pill From Eli Lilly Leads to Weight Loss and May Be Available Next Year
In a trial, the daily GLP-1 pill showed "significant" results and similar side effects to injectable GLP-1 drugs like Ozempic ...
The Print on MSN11h
In battle for Indian anti-obesity market, Eli Lilly’s pre-filled pen on one side, Novo Nordisk’s on other
India's anti-obesity drug market is currently valued at Rs 3,000-3,500 crore & is projected to grow nearly eightfold by 2030, ...
heraldsun.com.au4d
New Eli Lilly diabetes, obesity pill may outperform Ozempic - Herald Sun
Eli Lilly research shows their new GLP-1 pill successfully lowered patient’s weight and blood sugars, with some patients responding so well their levels no longer met the threshold for diabetes.
Today3d
Eli Lilly's New Weight Loss Pill May Be Available Next Year
A GLP-1 in pill form from Eli Lilly shows promising results for weight loss and Type 2 diabetes treatment in a trial. FDA approval is expected in 2026.